Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia
Autore:
Jonkers, IJ; de Man, FH; van der Laarse, A; Frolich, M; Leuven, JAG; Kamper, AM; Blauw, GJ; Smelt, AH;
Indirizzi:
Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RC NL-2300 RC Leiden, Netherlands Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RC NL-2300 RC Leiden, Netherlands Leiden Univ, Med Ctr, Dept Clin Chem, NL-2300 RC Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RC NL-2300 RC Leiden, Netherlands TNO, PG, Gaubius Lab, Leiden, Netherlands TNO Leiden NetherlandsTNO, PG, Gaubius Lab, Leiden, Netherlands
Titolo Testata:
JOURNAL OF HYPERTENSION
fascicolo: 4, volume: 19, anno: 2001,
pagine: 749 - 755
SICI:
0263-6352(200104)19:4<749:BRHRAB>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIUM-DEPENDENT VASODILATION; INSULIN-RESISTANCE; OXIDATIVE STRESS; FATTY-ACIDS; HYPERTENSION; DISEASE; SENSITIVITY; THERAPY; PLASMA; PATHOGENESIS;
Keywords:
endothelium; blood pressure; hypertriglyceridemia; endothelin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Jonkers, IJ Leiden Univ, Med Ctr, Dept Gen Internal Med, C2-R-132A,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands Leiden Univ C2-R-132A,Albinusdreef 2,POB 9600 Leiden Netherlands NL-2300 RC
Citazione:
I.J. Jonkers et al., "Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia", J HYPERTENS, 19(4), 2001, pp. 749-755

Abstract

Objective In hypertriglyceridemic patients, hypertension occurs frequentlyand may be associated with hyperinsulinemia and elevated plasma levels of free fatty acids (FFA), Besides the lipid-lowering effects. fibrates have been shown to reduce blood pressure in hypertensive patients. The present study was undertaken to investigate the effects of bezafibrate on hemodynamics in relation to insulin, FFA, sympathetic activity, renal sodium absorption, cyclic-GMP (cGMP) and endothelin-l in hypertriglyceridemic patients. Subjects and methods Hypertriglyceridemic patients (17) were randomized toreceive in a double-blind placebo-controlled study bezafibrate or placebo for 6 weeks. At the end of both treatment periods, blood pressure and heartrate were measured automatically. Plasma insulin, FFA, aldosterone, catecholamines, cGMP, endothelin-l levels and 24 h urine catecholamines and sodium excretion were assessed. Results Bezafibrate therapy decreased serum triglycerides (-65%, P < 0.001) and hemodynamic parameters: heart rate decreased from 69 to 66/min (P = 0,009), systolic blood pressure from 137 to 132 mmHg (P = 0,01), diastolic blood pressure from 81 to 79 mmHg (P = 0.07) and mean blood pressure from 102 to 99 mmHg (P = 0.06), Bezafibrate therapy reduced FFA and insulin (-55 and -57% respectively, both P < 0,001), while sympathetic activity and renalsodium absorption were not affected. cGMP increased (+17%, P = 0.008), whereas endothelin-l levels tended to decrease upon bezafibrate therapy (-10%,P = 0.077)Conclusion Bezafibrate reduces heart rate, blood pressure, insulin and FFAin hypertriglyceridemic patients. The hemodynamic effects cannot be attributed to changes in sympathetic activity or renal sodium absorption. Instead, based on the increase in plasma cGMP levels, the bezafibrate-induced hemodynamic effects are most likely to be caused by bezafibrate-induced improvement of endothelial function, (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 04:43:49